(redirected from ESAS)
Also found in: Dictionary, Financial, Acronyms, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for ESE

the compass point midway between east and southeast

References in periodicals archive ?
The Snowflake Republican argued that the voters' overwhelming rejection of Proposition 305, a ballot referral to block a 2017 law expanding access to the ESA program, sent a different message to lawmakers.
"This is still a very preliminary conclusion of our technical investigations," said David Parker, the ESA's Director of Human Spaceflight and Robot Exploration.
Despite this, there are ways to make the most of excess RMDs, and funneling these RMDs into an education savings account (ESA) is one recently revived strategy that is often overlooked.
ESAS and NZClear are real-time gross settlement systems ('RTGS').
Synchronization can be easily implemented and applied even when using the shorter duration ESAs, which would require synchronizing ESA administration on a weekly or twice weekly regimen.
Environmental Data Resources reported 11,969 Phase 1 ESAs in the third quarter in 13 western states, a 10.4 percent increase over one year prior.
Like 529 plans, Coverdell ESAs are funded with after tax dollars, and investment income is untaxed.
The review found that investigators who had not received any funding were more likely to identify Epo receptors on solid tumor cells, changes in cellular function, and Epo-induced signaling events, compared with researchers who had received funds from manufacturers of ESA's.
* Before making a decision regarding the use of ESAs, an appropriate history, physical examination, and diagnostic tests should be conducted to identify alternative causes of anemia aside from chemotherapy or an underlying hematopoietic malignancy.
The two companies are slated to launch their ESA APPRISE Oncology Program for cancer patients on March 24.
In addition to patient compliance, injection site pain may also influence a patient's preference for a particular ESA treatment.
Amgen manufactures the three ESAs currently marketed in the United States, two epoetin alfa products (Procrit and Epogen) and darbepoetin alfa (Aranesp).
Other approved indications for ESAs include the treatment of anemia associated with chronic renal failure; epoetin alfa has been approved for use with zidovudine therapy in patients with AIDS and for presurgical administration to reduce perioperative transfusion requirements.
The labeling changes, which incorporate advice from FDA advisory committees and expand upon labeling changes made in March 2007, also include a statement that symptoms of anemia, fatigue and quality of life have not been shown to improve in patients with cancer who are treated with ESAs.
These drugs are called erythropoiesis-stimulating agents (ESAs).